Bayer, AHA unite for cardiovascular studies
The investment will be allocated towards three AHA-Bayer Discovery Target Grants to be administered in 2017. AHA expects to make its official request for applications early in 2017.
"While we have made great progress in preventing and effectively treating cardiovascular diseases, there is still a great deal of research to be done," AHA CEO Nancy Brown said. "We are proud to collaborate with Bayer on this program and in our shared mission to advance innovation and transform foundational science to meet the needs of patients with limited treatment options."
Bayer has been a longtime sponsor of AHA, with a strong pipeline of research resources and opportunities for advancement in addressing cardiovascular and kidney diseases like heart failure, diabetic kidney disease and thrombosis. The range of disorders is wide, and the two organizations hope to address conditions requiring attention by applying their collective efforts.
"Our collaboration with the AHA underscores Bayer's history and long-standing commitment to advancing scientific research in cardiovascular and kidney disease management," Karl Ziegelbauer, head of therapeutic research groups in drug discovery in Bayer AG's pharmaceutical division, said. "These grants will help support innovative research that can improve our understanding of these conditions and identify ways we can collaborate to find therapeutic solutions for these underserved diseases."
Organizations in this story
American Heart Association 7272 Greenville Ave Dallas, TX - 75231-5129